13 March 2025
Hemogenyx
Pharmaceuticals plc
("Hemogenyx Pharmaceuticals" or the "Company")
Conversion of convertible loan notes and admission of
shares
Hemogenyx Pharmaceuticals plc (LSE:
HEMO) is pleased to announce that, further to its announcement on
19 February 2025, the convertible loan notes ("CLNs") automatically
converted on 8 March 2025 into 95,000 ordinary shares ("CLN
Shares").
An application has been made to the
Main Market of the London Stock Exchange, and admission of the CLN
Shares to trading is expected on 14 March 2025 ("Admission"). The
CLN Shares will rank pari
passu with the Company's existing Ordinary
Shares.
Total Voting Rights
For the purpose of the Disclosure
Guidance and Transparency Rules, following Admission the enlarged
issued share capital of the Company will comprise 3,699,539
ordinary shares. The Company does not hold any shares in treasury.
The above figure may be used by shareholders as the denominator for
the calculations by which they will determine if they are required
to notify their interest in, or a change to their interest in, the
Company, under the Disclosure Guidance and Transparency
Rules.
Market Abuse Regulation (MAR)
Disclosure
Certain information contained in
this announcement would have been inside information for the
purposes of Article 7 of Regulation No 596/2014
(as it forms part of UK domestic law by virtue of the European
Union (Withdrawal) Act 2018) until the release of this
announcement. The person responsible for arranging for the release
of this announcement on behalf of Hemogenyx Pharmaceuticals plc is
Dr Vladislav Sandler, Chief Executive Officer &
Co-Founder.
Enquiries:
|
Hemogenyx Pharmaceuticals
plc
|
https://hemogenyx.com
|
|
Dr Vladislav Sandler, Chief
Executive Officer & Co-Founder
|
headquarters@hemogenyx.com
|
|
Peter Redmond, Director
|
peter.redmond@hemogenyx.com
|
|
SP Angel Corporate Finance
LLP
|
Tel: +44 (0)20 3470 0470
|
|
Matthew Johnson, Vadim Alexandre,
Adam Cowl
|
|
|
Peterhouse Capital
Limited
|
Tel: +44 (0)20 7469 0930
|
|
Lucy Williams, Duncan Vasey, Charles
Goodfellow
|
|
About Hemogenyx Pharmaceuticals
plc
Hemogenyx Pharmaceuticals is a
publicly traded company (LSE: HEMO) headquartered
in London,
with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC
and Immugenyx LLC, located in New York
City at its state-of-the-art research
facility.
The Company is a clinical stage
biopharmaceutical group developing new medicines and treatments to
treat blood and autoimmune diseases. Hemogenyx Pharmaceuticals is
developing several distinct and complementary product candidates,
as well as platform technologies that it uses as engines for novel
product development.
